Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3386460004
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- 450
- Dividend yield
- Not available
- Beta
- 1.12
About
About Kidswell Bio Corporation
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
Visit company website
5 years, 6 months ago
Gene Techno Science Co.,Ltd is currently in a long term uptrend where the price is trading 7.6% above its 200 day moving average.
From a valuation standpoint, the stock is 80.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Gene Techno Science Co.,Ltd's total revenue rose by 30.3% to $546M since the same quarter in the previous year.
Its net income has increased by 107.4% to $25M since the same quarter in the previous year.
Based on the above factors, Gene Techno Science Co.,Ltd gets an overall score of 4/5.